TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Instagram Outage Disrupts Thousands of U.S. Users 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
New York, Jan. 08, 2018 -- Progyny, the leading fertility benefits management company, today announced it has achieved over 100% revenue growth in 2017. Progyny’s innovative carve-out fertility benefits solution for the self-insured market is experiencing rapid adoption by many of the nation’s top employers. Based on current sales momentum, Progyny expects to double its customer base and revenue again in 2018.
In the latest FertilityIQ Family Builder Workplace Index, employers offering Progyny’s inclusive, comprehensive benefit ranked at the top of their respective industries.
The need for fertility treatment is widespread and growing. There are several societal trends fueling this market growth.
- The ability to achieve pregnancy dramatically decreases with age and according to the CDC, for the first time in history, the 2016 US birth rate of women aged 30 to 34 surpassed the birth rate for women aged 25 to 29. It’s estimated infertility impacts 1 in every 8 women of childbearing age.
- There is growing legal and social acceptance for LGBT family-building and single parenting by choice, which requires use of fertility treatment.
- Fertility preservation is top of mind with young women. According to a study on infertility, 73% of millennials would pursue egg freezing if the option was available.
“The nation’s leading employers are recognizing the importance of providing a comprehensive and effective fertility benefit that works for their entire diverse workforce,” said David Schlanger, CEO. “The Progyny solution couples the latest science and best practices with concierge-level clinical and emotional support for patients. This combination improves pregnancy outcomes and reduces total fertility-related costs.”
On January 10, 2018, at 4:00 p.m. PT, David Schlanger will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference. The presentation will take place at the invitation-only event being held at San Francisco’s Westin St. Francis Hotel.
Progyny’s lead investors include Kleiner Perkins (KP), TPG Biotech and SR One.
About Progyny:
Progyny is a leading fertility benefits management company that combines service, science, technology and data to provide comprehensive value based fertility solutions for self-insured employers.
Progyny’s benefit plans are designed to improve outcomes, shorten time to pregnancy and reduce total fertility-related costs. Progyny is privately held and is headquartered in New York, NY, with operations in San Francisco, CA. Please visit www.progyny.com.
###
Selena Yang [email protected] 646-768-9719
